GLP-1 Side Effects Week by Week: What the Trials Actually Recorded

Published July 18, 2026

The Number vs. the Timeline

"44% get nausea" is technically accurate and practically useless. It doesn't tell you when, how bad, or for how long — the three things a person deciding whether to start (or quit) actually needs.

The trials recorded all three. Here's the timeline they documented, mapped to the standard titration schedule.

Weeks 1–4: The Introduction (0.25mg semaglutide / 2.5mg tirzepatide)

Starting doses are deliberately sub-therapeutic — they exist to let your GI tract adapt. Most patients report mild appetite change and, for a subset, intermittent nausea, often worse on the day or two after injection. Trial severity data: overwhelmingly mild. What helps, per both trial protocols and clinical practice: smaller meals, less fat, slower eating, hydration.

Weeks 5–16: The Climb (dose escalations)

Each step up re-triggers the adjustment. This is where the 44% figure concentrates — and where the discontinuation risk lives. The 2025 JAMA adherence study found moderate-to-severe GI events raised quit hazard 19–38%. Yet in the controlled trials, where patients had scheduled clinical contact, fewer than 1 in 20 stopped for GI reasons. Same drug, same biology, different support structure, wildly different outcomes.

The practical moves during escalation: your provider can hold a dose longer before stepping up (titration schedules are guidance, not law), shift injection timing, or address specific symptoms directly. All of that requires a provider you can actually reach — which is the difference between a program and a checkout page.

Week 17 Onward: The Plateau of Tolerance

At maintenance dose, both trials show adverse-event rates falling toward baseline. The body adapts. Most patients who cross the titration period describe maintenance as uneventful — which is why the quit-decision math is so lopsided: the hardest part is front-loaded, and the benefit (14.9%–20.9% mean weight loss at 68–72 weeks) is back-loaded.

When Symptoms Are Not Routine

Severe or persistent abdominal pain, repeated vomiting with dehydration, or symptoms of pancreatitis or gallbladder disease are not titration effects — they warrant prompt medical attention, and they're screened for in any legitimate intake. This is also why provider review before prescribing isn't bureaucracy: contraindication screening exists because these medications, like all effective ones, have real edges.

Frequently Asked Questions

How long does semaglutide nausea last?

In the trials it clustered during dose-escalation weeks and diminished at stable dosing — typically days per episode, concentrated in the first months, not the whole treatment.

What percentage of people get side effects?

STEP 1: ~44% nausea, ~30% diarrhea, mostly mild-to-moderate. SURMOUNT-1 tirzepatide figures were comparable, dose-dependent.

How many people quit because of side effects?

Under 5% in the trials — versus much higher real-world discontinuation, a gap largely attributed to support access. See why most people quit GLP-1s.

Do compounded versions have the same side effects?

Side-effect data comes from FDA-approved formulations; compounded products contain the same active ingredient when properly sourced but lack trial data. Discuss with a licensed provider — Ozari's intake screens every patient.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved. Clinical trial results describe FDA-approved formulations in study populations and are not guarantees of individual outcomes. Always consult a licensed healthcare provider before starting, changing, or stopping any prescription medication.

Sources

safety